Tags

Type your tag names separated by a space and hit enter

Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
J Pharm Sci. 2018 04; 107(4):984-998.JP

Abstract

The potential of the force control agent magnesium stearate (MgSt) to enhance the aerosol performance of lactose-based dry powder inhaled (DPI) formulations was investigated in this study. The excipient-blends were investigated with analytical techniques including time-of-flight secondary ion mass spectrometry and single particle aerosol mass spectrometry (SPAMS), and particle size, morphology, and surface properties were evaluated. Excipient-blends were manufactured either by high-shear or low-shear blending lactose carrier with different amounts of MgSt in the range from 0% to 10% (w/w). Fluticasone propionate (FP) and salmeterol xinafoate (SX) used as model active pharmaceutical ingredients were added by low-shear mixing. The in vitro aerosol performance in terms of aerodynamic particle size distribution and fine particle fraction (FPF) of the FP and SX DPI formulations was evaluated with the Next Generation Impactor and also with SPAMS using a Breezhaler® inhalation device. The distribution of MgSt on the lactose carrier in the blends was visualized and found to depend strongly on the blending method. This affected drug particle detachment from the carrier and thus impacted aerosol performance for FP and SX. Compared with blends without force control agent, low-shear blending of MgSt increases the FPF of the model drug SX, whereas high-shear blending significantly increased FPF of both SX and FP. The interactions between drug and carrier particles were substantially affected by the choice of blending technique of MgSt with lactose. This allows detailed control of aerosol performance of a DPI by an adequate choice of the blending technique. SPAMS successfully demonstrated that it is capable to distinguish changes in DPI formulations blended with different amounts of MgSt, and additional information in terms of dispersibility of fine particles could be generated.

Authors+Show Affiliations

Novartis Pharma AG - Global Development, Novartis Campus, 4056 Basel, Switzerland; Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland. Electronic address: martin.jetzer@novartis.com.Novartis Pharma AG - Global Development, Novartis Campus, 4056 Basel, Switzerland.Novartis Pharma AG - Global Development, Novartis Campus, 4056 Basel, Switzerland.Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland; University of Applied Sciences and Arts Northwestern Switzerland (FHNW), School of Life Sciences, Institute of Pharmaceutical Technology, Gründenstrasse 40, 4132 Muttenz, Switzerland.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29247741

Citation

Jetzer, Martin W., et al. "Investigations On the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations." Journal of Pharmaceutical Sciences, vol. 107, no. 4, 2018, pp. 984-998.
Jetzer MW, Schneider M, Morrical BD, et al. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations. J Pharm Sci. 2018;107(4):984-998.
Jetzer, M. W., Schneider, M., Morrical, B. D., & Imanidis, G. (2018). Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations. Journal of Pharmaceutical Sciences, 107(4), 984-998. https://doi.org/10.1016/j.xphs.2017.12.006
Jetzer MW, et al. Investigations On the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations. J Pharm Sci. 2018;107(4):984-998. PubMed PMID: 29247741.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations. AU - Jetzer,Martin W, AU - Schneider,Marcel, AU - Morrical,Bradley D, AU - Imanidis,Georgios, Y1 - 2017/12/14/ PY - 2017/09/29/received PY - 2017/11/21/revised PY - 2017/12/01/accepted PY - 2017/12/17/pubmed PY - 2018/9/11/medline PY - 2017/12/17/entrez KW - blending method KW - dispersibility KW - dry powder inhaler (DPI) KW - force control agent (FCA) KW - next generation impactor (NGI) KW - single particle aerosol mass spectrometry (SPAMS) KW - time-of-flight secondary ion mass spectrometry (ToF-SIMS) SP - 984 EP - 998 JF - Journal of pharmaceutical sciences JO - J Pharm Sci VL - 107 IS - 4 N2 - The potential of the force control agent magnesium stearate (MgSt) to enhance the aerosol performance of lactose-based dry powder inhaled (DPI) formulations was investigated in this study. The excipient-blends were investigated with analytical techniques including time-of-flight secondary ion mass spectrometry and single particle aerosol mass spectrometry (SPAMS), and particle size, morphology, and surface properties were evaluated. Excipient-blends were manufactured either by high-shear or low-shear blending lactose carrier with different amounts of MgSt in the range from 0% to 10% (w/w). Fluticasone propionate (FP) and salmeterol xinafoate (SX) used as model active pharmaceutical ingredients were added by low-shear mixing. The in vitro aerosol performance in terms of aerodynamic particle size distribution and fine particle fraction (FPF) of the FP and SX DPI formulations was evaluated with the Next Generation Impactor and also with SPAMS using a Breezhaler® inhalation device. The distribution of MgSt on the lactose carrier in the blends was visualized and found to depend strongly on the blending method. This affected drug particle detachment from the carrier and thus impacted aerosol performance for FP and SX. Compared with blends without force control agent, low-shear blending of MgSt increases the FPF of the model drug SX, whereas high-shear blending significantly increased FPF of both SX and FP. The interactions between drug and carrier particles were substantially affected by the choice of blending technique of MgSt with lactose. This allows detailed control of aerosol performance of a DPI by an adequate choice of the blending technique. SPAMS successfully demonstrated that it is capable to distinguish changes in DPI formulations blended with different amounts of MgSt, and additional information in terms of dispersibility of fine particles could be generated. SN - 1520-6017 UR - https://www.unboundmedicine.com/medline/citation/29247741/Investigations_on_the_Mechanism_of_Magnesium_Stearate_to_Modify_Aerosol_Performance_in_Dry_Powder_Inhaled_Formulations_ DB - PRIME DP - Unbound Medicine ER -